ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 2185

Prevalence of Severe Extra-Glandular Manifestations in a Large Cohort of Patients with Primary Sjögren’s Syndrome

Chiara Baldini1, Pasquale Pepe2, Luca Quartuccio3, Roberta Priori4, Elena Bartoloni Bocci5, Alessia Alunno6, Serena Colafrancesco7, Angelica Gattamelata8, Marta Maset9, Mariagrazia Modesti7, Antonio Tavoni10, Salvatore De Vita9, Roberto Gerli5, Guido Valesini7 and Stefano Bombardieri11, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, 3Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, 4Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, 5Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, 6Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, 7Rheumatology Unit, Sapienza University of Rome, Rome, Italy, 8Sapienza University of Rome, Rome, Italy, 9Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, 10University of Pisa, Immunoallergology Unit, Pisa, Italy, 11Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Sjogren's syndrome

Session Information

Title: Sjögren's Syndrome - Clinical

Session Type: Abstract Submissions (ACR)

Background/Purpose:

i) to describe the clinico- serological features of a cohort of 1115 patients with primary Sjögren’s syndrome (pSS); ii) to assess the prevalence of systemic extra-glandular manifestations in the cohort; iii) to estimate the impact of the serological and immunological patients’ features on disease different phenotypes and on the utilization of immunosuppressive drugs

Methods: The case records of 1115 patients with a diagnosis of pSS attending four Italian reference centers were reviewed. Clinical and laboratory data of the patients enrolled were retrieved according to a standard form. Independent risk factors for glandular and extra-glandular disease manifestations were identified by logistic regression.

Results: The cohort consisted of 1115 pSS patients (1067 F: 48 M;  mean age at the diagnosis of 51.6±13.8 yrs; mean follow-up 5.8±6.5 yrs). All the patients included fulfilled the European classification criteria for pSS, while the AECG criteria were fulfilled in 926/1115 (83%) cases. Xerostomia (93%), xerophtalmia (95%) and articular involvement (62%) were the most commonly detected clinical manifestations followed by hematological involvement (32%) and salivary gland enlargement (31%). A systemic extra-glandular involvement was diagnosed in 475/1115 (42%) patients. Severe extraglandular manifestations included: active synovitis (11%), axonal sensory-motor neuropathy (2%), diffuse purpura or ulcers (6%) renal involvement (0.7%), myositis (0.5%), cerebral vasculitis (0.5%) and transverse myelitis (0.2%). Finally, 50 cases of non-Hodgkin lymphoma were documented. Patients with a systemic disease had a lower mean age at diagnosis (p=0.002), a longer follow up (p<0.0001) and a higher frequency of serologic markers (ANA, RF, anti-Ro/SS-A antibodies, anti-LA/SS-B antibodies, cryoglobulins, hypergammaglobulinemia, low C3/C4 levels) in the univariate analysis. The adjusted multivariate analysis identified as independent serological risk factors for severe extraglandular involvement: low C3 (OR 2.6, 95% CI 1.6-4.1), low C4 (OR1.9, 95% CI 1.1-3.3), hypergammaglobulinemia (OR 2.1, 95% CI 1.5-2.9), cryoglobulins (OR 7.6, 95% CI 2.6-22.3), Rheumatoid factor (OR 2.5, 95% CI 1.5-22.9). No correlation was found among pSS extraglandular involvement and fulfillment of the AECG criteria or positive minor salivary gland biopsy at the diagnosis. 

Conclusion: Although the hallmark features of pSS are represented by glandular manifestations, this study support the evidence that severe systemic manifestations may occur in about the 20% of the patients. Patients presenting an active serological profile should be more closely monitored and may deserve more aggressive immunosuppressive drugs.


Disclosure:

C. Baldini,
None;

P. Pepe,
None;

L. Quartuccio,
None;

R. Priori,
None;

E. Bartoloni Bocci,
None;

A. Alunno,
None;

S. Colafrancesco,
None;

A. Gattamelata,
None;

M. Maset,
None;

M. Modesti,
None;

A. Tavoni,
None;

S. De Vita,
None;

R. Gerli,
None;

G. Valesini,
None;

S. Bombardieri,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-severe-extra-glandular-manifestations-in-a-large-cohort-of-patients-with-primary-sjogrens-syndrome/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology